Neuroderm Ltd Company Profile (NASDAQ:NDRM)

About Neuroderm Ltd (NASDAQ:NDRM)

Neuroderm Ltd logoNeuroDerm Ltd. is an Israel-based clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson's disease, as well as other CNS diseases. The Company's Parkinson's disease product candidates are drug-device combination products, with devices and varying levodopa (LD)/carbidopa (CD) or apomorphine concentrations and dosages. Its liquid LD/CD and apomorphine formulations include ND0612H, ND0612L and ND0701. It is developing ND0612H for the treatment of patients suffering from severe Parkinson's disease. It is developing ND0612L for the treatment of patients at the moderate stage of Parkinson's disease that can no longer control motor complications with oral levodopa. It has also designed ND0701, which is an apomorphine-based product. ND0701 is for patients suffering from Parkinson's disease, may be used mostly by patients suffering from high motor fluctuations and not responding well to LD/CD.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:NDRM
  • CUSIP: N/A
  • Web:
  • Market Cap: $561 million
  • Outstanding Shares: 26,338,000
Average Prices:
  • 50 Day Moving Avg: $25.43
  • 200 Day Moving Avg: $23.50
  • 52 Week Range: $15.10 - $30.45
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -13.40
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $5.31 per share
  • Price / Book: 4.01
  • EBIDTA: ($40,700,000.00)
  • Return on Equity: -32.12%
  • Return on Assets: -30.45%
  • Current Ratio: 15.77%
  • Quick Ratio: 15.77%
  • Average Volume: 263,872 shs.
  • Beta: 0.94
  • Short Ratio: 2.03

Frequently Asked Questions for Neuroderm Ltd (NASDAQ:NDRM)

What is Neuroderm Ltd's stock symbol?

Neuroderm Ltd trades on the NASDAQ under the ticker symbol "NDRM."

How were Neuroderm Ltd's earnings last quarter?

Neuroderm Ltd (NASDAQ:NDRM) announced its earnings results on Thursday, May, 11th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.13. View Neuroderm Ltd's Earnings History.

Where is Neuroderm Ltd's stock going? Where will Neuroderm Ltd's stock price be in 2017?

6 analysts have issued twelve-month price objectives for Neuroderm Ltd's shares. Their predictions range from $30.00 to $70.00. On average, they anticipate Neuroderm Ltd's stock price to reach $43.75 in the next twelve months. View Analyst Ratings for Neuroderm Ltd.

What are analysts saying about Neuroderm Ltd stock?

Here are some recent quotes from research analysts about Neuroderm Ltd stock:

  • 1. According to Zacks Investment Research, "Neuroderm Ltd. is a clinical-stage pharmaceutical company. It is developing next-generation treatments for central nervous system (CNS) disorders. The Company develops liquid levodopa (LD), which is a treatment for Parkinson's disease (PD). Its product pipelines includes ND0612L for moderate PD, ND0612H for severe PD, ND0680 for severe PD, ND0701 for severe PD and ND0801for Cognitive Disorders. NeuroDerm Ltd. is headquartered in Rehovot, Israel. " (4/5/2017)
  • 2. Cowen and Company analysts commented, "Neuroderm announced the preliminary Phase II results for ND0612H, and importantly, the initial feedback from our consultants has been very positive. In general, our consultants believe the efficacy looks comparable to Duodopa, but with a significantly improved use and safety profile. These data substantially de-risk the program. The current valuation is dramatically understated." (3/1/2017)

Are investors shorting Neuroderm Ltd?

Neuroderm Ltd saw a increase in short interest in the month of May. As of May 15th, there was short interest totalling 1,068,368 shares, an increase of 8.5% from the April 28th total of 984,479 shares. Based on an average daily trading volume, of 203,361 shares, the days-to-cover ratio is currently 5.3 days.

Who are some of Neuroderm Ltd's key competitors?

Who are Neuroderm Ltd's key executives?

Neuroderm Ltd's management team includes the folowing people:

  • Robert Taub, Chairman of the Board
  • Oded S. Liebermann, Chief Executive Officer, Director
  • Roy Golan CPA, Chief Financial Officer
  • Tami Yardeni, Chief Operating Officer
  • Sharon Cohen-Vered Ph.D., Vice President - CMC & QA
  • Sheila Oren, Vice President - Clinical and Regulatory Affairs
  • Eran Shor, Vice President - Devices
  • Oron Yacoby-Zeevi, Vice President - Research & Development
  • Revital Mandil-Levin Ph.D., Head - Business Development
  • Shmuel Cabilly, Director

When did Neuroderm Ltd IPO?

(NDRM) raised $45 million in an initial public offering on Friday, November 14th 2014. The company issued 4,500,000 shares at a price of $10.00 per share. Jefferies and Cowen and Company served as the underwriters for the IPO and Oppenheimer and Roth Capital Partners were co-managers.

Who owns Neuroderm Ltd stock?

Neuroderm Ltd's stock is owned by many different of institutional and retail investors. Top institutional investors include Redmile Group LLC (3.51%), Menora Mivtachim Holdings LTD. (2.59%), Nexthera Capital LP (1.09%), OppenheimerFunds Inc. (1.09%), FMR LLC (0.76%) and Bailard Inc. (0.41%). View Institutional Ownership Trends for Neuroderm Ltd.

Who sold Neuroderm Ltd stock? Who is selling Neuroderm Ltd stock?

Neuroderm Ltd's stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, Menta Capital LLC, Parametric Portfolio Associates LLC, Victory Capital Management Inc., Swiss National Bank, Renaissance Technologies LLC, Bank of America Corp DE and Morgan Stanley. View Insider Buying and Selling for Neuroderm Ltd.

Who bought Neuroderm Ltd stock? Who is buying Neuroderm Ltd stock?

Neuroderm Ltd's stock was acquired by a variety of institutional investors in the last quarter, including Nexthera Capital LP, OppenheimerFunds Inc., FMR LLC, Menora Mivtachim Holdings LTD., Credit Suisse AG, NJ State Employees Deferred Compensation Plan, Bank of Montreal Can and Bailard Inc.. View Insider Buying and Selling for Neuroderm Ltd.

How do I buy Neuroderm Ltd stock?

Shares of Neuroderm Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Neuroderm Ltd's stock price today?

One share of Neuroderm Ltd stock can currently be purchased for approximately $21.30.

MarketBeat Community Rating for Neuroderm Ltd (NASDAQ NDRM)
Community Ranking:  3.3 out of 5 (  )
Outperform Votes:  91 (Vote Outperform)
Underperform Votes:  46 (Vote Underperform)
Total Votes:  137
MarketBeat's community ratings are surveys of what our community members think about Neuroderm Ltd and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Neuroderm Ltd (NASDAQ:NDRM) (?)
Ratings Breakdown: 3 Hold Ratings, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $43.75 (105.40% upside)

Analysts' Ratings History for Neuroderm Ltd (NASDAQ:NDRM)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/14/2017Oppenheimer Holdings Inc.Reiterated RatingHoldMediumView Rating Details
4/24/2017Jefferies Group LLCReiterated RatingBuy$42.00HighView Rating Details
4/1/2017Roth CapitalSet Price TargetBuy$33.00HighView Rating Details
3/7/2017CIBCReiterated RatingOutperform -> Market PerformN/AView Rating Details
3/7/2017Citigroup IncDowngradeOutperform -> Market PerformN/AView Rating Details
3/1/2017Cowen and CompanyBoost Price TargetOutperform$38.00 -> $70.00N/AView Rating Details
11/10/2015Raymond James Financial, Inc.Initiated CoverageOutperform$28.00N/AView Rating Details
(Data available from 5/29/2015 forward)


Earnings History for Neuroderm Ltd (NASDAQ:NDRM)
Earnings by Quarter for Neuroderm Ltd (NASDAQ:NDRM)
Earnings History by Quarter for Neuroderm Ltd (NASDAQ:NDRM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/11/20173/31/2017($0.38)($0.25)ViewN/AView Earnings Details
3/30/201712/31/2016($0.46)($0.49)ViewN/AView Earnings Details
11/10/20169/30/2016($0.42)($0.42)ViewN/AView Earnings Details
8/25/2016Q2($0.32)($0.32)ViewListenView Earnings Details
5/26/2016Q1($0.35)($0.25)ViewListenView Earnings Details
3/31/2016Q4($0.29)($0.31)ViewListenView Earnings Details
11/11/2015Q315($0.34)($0.07)ViewListenView Earnings Details
8/6/2015Q215($0.20)($0.34)ViewListenView Earnings Details
5/27/2015Q115($0.28)($0.09)ViewListenView Earnings Details
4/2/2015Q4 2014($0.35)($2.55)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Neuroderm Ltd (NASDAQ:NDRM)
2017 EPS Consensus Estimate: ($1.86)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.40)($0.40)($0.40)
Q2 20172($0.51)($0.40)($0.46)
Q3 20172($0.51)($0.50)($0.51)
Q4 20172($0.50)($0.50)($0.50)
(Data provided by Zacks Investment Research)


Dividend History for Neuroderm Ltd (NASDAQ:NDRM)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Neuroderm Ltd (NASDAQ:NDRM)
No insider trades for this company have been tracked by


Headline Trends for Neuroderm Ltd (NASDAQ:NDRM)
Latest Headlines for Neuroderm Ltd (NASDAQ:NDRM)
DateHeadline logoNeuroderm Ltd (NDRM) Short Interest Update - May 29 at 7:56 AM logoNeuroderm Ltd (NDRM) Receives Consensus Recommendation of "Hold" from Brokerages - May 26 at 11:13 AM logoNeuroDerm (NDRM) Says ND0612H Phase II Trial Results to be Presented in Late-Breaking Session at MDS Congress - - May 24 at 6:53 PM logoNeuroDerm (NDRM) Says ND0612H Phase II Trial Results to be Presented in Late-Breaking Session at MDS Congress - May 24 at 10:29 AM logoNeuroDerm ND0612H Phase II Trial Results to be Presented in Late-Breaking Session at the 21st International Congress of Parkinson’s Disease and Movement Disorders - May 23 at 10:15 AM logo Analysts Anticipate Neuroderm Ltd (NDRM) Will Announce Earnings of -$0.45 Per Share - May 17 at 4:18 PM logoNeuroderm Ltd to Post Q2 2017 Earnings of ($0.51) Per Share, Oppenheimer Holdings Forecasts (NDRM) - May 17 at 7:46 AM logoFY2019 Earnings Estimate for Neuroderm Ltd (NDRM) Issued By Oppenheimer Holdings - May 16 at 1:26 PM logoNeuroderm Ltd (NDRM) Issues Earnings Results - May 11 at 3:00 PM logoNeuroDerm reports 1Q loss - May 11 at 9:28 AM logoNeuroDerm Announces First Quarter 2017 Financial Results - May 11 at 9:28 AM logoNeuroderm (NDRM) Earns Daily Media Impact Rating of -0.09 - May 4 at 12:06 PM logoNeuroderm (NDRM) Receiving Favorable Media Coverage, Report Finds - May 1 at 4:56 PM logoNeuroderm Ltd (NDRM) Receives Average Recommendation of "Hold" from Brokerages - May 1 at 2:32 PM logoNeuroderm (NDRM) Earns Media Impact Score of -0.20 - April 27 at 3:08 PM logoZacks: Analysts Expect Neuroderm Ltd (NDRM) to Announce -$0.38 Earnings Per Share - April 27 at 1:11 AM logoFY2017 EPS Estimates for Neuroderm Ltd (NDRM) Reduced by Jefferies Group - April 26 at 1:12 PM logoJefferies Group LLC Reaffirms Buy Rating for Neuroderm Ltd (NDRM) - April 24 at 10:10 PM logoNeuroderm (NDRM) Earning Positive News Coverage, Study Finds - April 24 at 4:32 PM logoNeuroderm's (NDRM) Hold Rating Reaffirmed at Oppenheimer Holdings Inc. - April 23 at 11:52 PM logoNeuroDerm Ltd. (Nasdaq: NDRM) to Ring The Nasdaq Stock Market Opening Bell - Nasdaq - April 22 at 6:11 PM logoNeuroDerm to Ring the Nasdaq Stock Market Opening Bell and Participate in the Parkinson’s Unity Walk - April 20 at 6:52 PM logoNeuroDerm Ltd. (Nasdaq: NDRM) to Ring The Nasdaq Stock Market Opening Bell - April 20 at 6:52 PM logoNeuroderm (NDRM) Receiving Critical News Coverage, Report Shows - April 20 at 8:45 AM logoPost Earnings Coverage as NeuroDerm Reported FY16 Results - April 12 at 9:13 AM logoNeuroDerm to Host Investor Day on April 21, 2017 - April 10 at 10:15 AM logoNeuroderm Ltd (NDRM) Expected to Announce Quarterly Sales of $0.00 - April 7 at 9:01 PM logoNeuroDerm Announces Fourth Quarter and Full Year 2016 Financial Results - April 7 at 11:27 AM logoNeuroderm Ltd (NDRM) Lowered to "Hold" at Zacks Investment Research - April 5 at 9:52 PM logo-$0.38 EPS Expected for Neuroderm Ltd (NDRM) This Quarter - April 5 at 4:07 PM logoNeuroderm Ltd (NDRM) Receives Consensus Recommendation of "Buy" from Brokerages - April 4 at 2:00 PM logoNeuroderm Ltd Expected to Earn Q2 2017 Earnings of ($0.42) Per Share (NDRM) - April 3 at 8:56 AM logoNeuroderm Ltd (NDRM) Given a $33.00 Price Target by Roth Capital Analysts - April 2 at 11:30 PM logoNeuroDerm reports 4Q loss - March 30 at 7:05 PM logoNeuroDerm Announces Fourth Quarter and Full Year 2016 Financial Results - March 30 at 7:05 PM logo7:05 am NeuroDerm reports Q4 results; remains on track to submit regulatory applications for ND0612 in the U.S. and EU in 2018 - March 30 at 7:05 PM logoQ4 2016 Neuroderm Ltd Earnings Release - Before Market Open - March 30 at 7:05 PM logoNeuroderm Ltd (NDRM) Announces Earnings Results, Misses Expectations By $0.03 EPS - March 30 at 9:49 AM logoNeuroderm's (NDRM) "Buy" Rating Reaffirmed at Jefferies Group LLC - March 30 at 8:19 AM logoNeuroderm Ltd (NDRM) Set to Announce Quarterly Earnings on Wednesday - March 28 at 8:23 AM logoNeuroderm Ltd (NDRM) Given Buy Rating at Jefferies Group LLC - March 25 at 7:50 AM logoNeuroDerm to Host Fourth Quarter and 2016 Fiscal Year Financial Results Conference Call on March 30, 2017 - March 21 at 11:34 AM logoNeuroderm Ltd (NDRM) Stock Rating Upgraded by Zacks Investment Research - March 7 at 10:39 PM logoNeuroDerm downgraded by Oppenheimer - March 7 at 6:37 PM logoCan The Uptrend Continue for NeuroDerm (NDRM)? - March 7 at 10:11 AM logoBUZZ-US STOCKS ON THE MOVE-Infrastructure stocks, Dynavax, NeuroDerm - Nasdaq - March 3 at 12:00 AM logoNeuroDerm's (NDRM) Phase II Trial of ND0612H in Parkinson's Achieves Primary Endpoint - - March 3 at 12:00 AM logoHealth Care Sector Update for 03/01/2017: NDRM,DVAX,IPXL - Nasdaq - March 3 at 12:00 AM logo7:00 am NeuroDerm achieves primary endpoint in ND0612H Phase II Trial for advanced parkinson's disease; seeks broader EU Label Based on iNDiGO trial following EMA meeting (shares halted) - March 2 at 6:59 PM logoNeuroDerm Ltd. (NDRM) Soared To A New High On Phase 2 Study Results - March 2 at 9:15 AM



Neuroderm Ltd (NDRM) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by Staff